Clopidosafe™
Enhance Your Treatment with Pharmacogenetic Testing

Clopidosafe™ — Enhance Your Treatment with Pharmacogenetic Testing

Understanding Clopidogrel and Clopidosafe™

Clopidogrel is an anti-platelet drug that reduces the stickiness of platelet and has beenshown to reduce the risk of cardiovascular disease (e.g, heart attack, stroke, peripheral vascular disease) and re-occlusion of blood vessels after stenting procedure of blood vessels of the heart. The efficacy of Clopidogrel is significantly influenced by genetic variations, particularly in the CYP2C19 gene¹. These variations can affect the metabolic activation of the drug, leading to variations in treatment outcomes².

Introducing Clopidosafe™

Our pharmacogenetic test, Clopidosafe™, is designed to identify these genetic variants, providing crucial insights into how well your body will respond to Clopidogrel. By understanding your unique genetic makeup, Clopidosafe™ can help ensure that you receive the most effective dosage for optimal health outcomes.

Potential Consequences of Varied Drug Efficacy

Without personalized testing, patients may not experience the full benefits of Clopidogrel, potentially leading to an increased risk of cardiovascular events. Following a stenting procedure, a combination treatment of clopidogrel and aspirin is recommended for 12 months to prevent recurrent cardiovascular events. Clopidogrel needs to be activated (or metabolised) by an enzyme (CYP2C19) in order to be effective which can be influenced by genetic factors. People carrying one (intermediate metabolizer) or two (poor metabolizer) ‘loss-of-function’ variants of the CYP2C19 gene who take clopidogrel have a higher risk of cardiovascular events compared to those without these variants. The prevalence of intermediate metabolizers is 45%, while that of poor metabolizers is 12% in population ³. Compared to standard care without use of genetic markers, clinical trials showed that the use of genetic markers to guide selection of anti-platelet drugs leads to lower incidence of cardiovascular events (Figure 1)⁴.However, there are alternatives in this drug class which are less influenced by these genetic variants, e.g. prasugrel or ticagrelor. Carriers of loss-of-function variants of CYP2C19 are recommended to take these alternative drugs. Clopidosafe™ aims to mitigate this risk by tailoring your treatment plan to your genetic profile.

Genetic-guided therapy resulted in a statistically significant 40% reduction in cumulative ischemic events compared with conventional clopidogrel therapy.(Figure 1)

Interpreting Your Clopidosafe™ Results

Understanding your Clopidosafe™ test results is key to optimizing your treatment with Clopidogrel. Here’s a breakdown of what the results mean:

Next Steps

Discuss your results with your healthcare provider to determine the best course of action. Your provider may suggest further tests, a modified treatment plan, or additional preventive measures based on your genetic profile and other factors associated with high on-treatment residual platelet aggregation.

Why Choose Clopidosafe™?

Customized treatment strategies based on your DNA

Personalized Medicine

Maximize the benefits of your medication

Enhanced Efficacy

Empower your decisions with
genetic knowledge

Informed Healthcare

Complete Your Journey with GemVCare

How it works

Specimens will be sent to our testing center for analysis and the test will be completed within 14 working days.

02

01 Collect specimens at designated centers

•Oral cell specimen / Blood specimen

03 Reports will be explained by your healthcare provider and an appropriate disease management plan will be designed accordingly.

References：

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22;360(4):354-62.
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27;304(16):1821-30.
Yu MHC, Chan MCY, Chung CCY, Li AWT, Yip CYW, Mak CCY, Chau JFT, Lee M, Fung JLF, Tsang MHY, Chan JCK, Wong WHS, Yang J, Chui WCM, Chung PHY, Yang W, Lee SL, Chan GCF, Tam PKH, Lau YL, Tang CSM, Yeung KS, Chung BHY. Actionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population. PLoS Genet. 2021 Feb 18;17(2):e1009323. doi: 10.1371/journal.pgen.1009323.
Ingraham BS, Farkouh ME, Lennon RJ, So D, Goodman SG, Geller N, Bae JH, Jeong MH, Baudhuin LM, Mathew V, Bell MR, Lerman A, Fu YP, Hasan A, Iturriaga E, Tanguay JF, Welsh RC, Rosenberg Y, Bailey K, Rihal C, Pereira NL. Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2023 Apr 10;16(7):816-825.

Clopidosafe™ Enhance Your Treatment with Pharmacogenetic Testing